Bradshawblackburn4208

Monocular and binocular UDVA was excellent in all three groups. Eyhance achieved binocular UIVA similar to that of Symfony, the latter showing the highest binocular UNVA. The defocus curves at -1 D were equivalent for both Eyhance and Symfony, whereas contrast sensitivity was similar in all three groups. The Eyhance spectacle independence score was comparable to Symfony's for intermediate-distance activities, the latter however achieving the worst results for halos and glare.

Enhanced monofocal Eyhance was not inferior to Symfony as regards intermediate-distance visual outcome and spectacle independence, also providing lower subjective perception of halos and glare.

Enhanced monofocal Eyhance was not inferior to Symfony as regards intermediate-distance visual outcome and spectacle independence, also providing lower subjective perception of halos and glare.

To assess the impact on visual development of multifocal versus monofocal intraocular lenses (IOLs) implantation in children following congenital cataract surgery.

Retrospective interventional consecutive case series.

We reviewed the records of 56 eyes of 43 pediatric patients who underwent congenital cataract surgery with phacoaspiration and simultaneous implantation of IOL under one year of age. Corrected distance visual acuity (CDVA), refractive error and ocular motility disorders were evaluated after a follow-up greater than 4 years.

We implanted 32 multifocal (18unilateral, Group A and 14bilateral, Group B) and 24monofocal IOLs (12unilateral, Group C and 12bilateral, Group D). Mean follow-up was 6.67 years. Mean CDVA of the eyes with multifocal IOL was 0.75±0.46 logMAR in unilateral cataract surgery and 0.34±0.25logMAR in bilateral ones; with monofocal IOLs was 0.71±0.52logMAR in unilateral and 0.53±0.43logMAR in bilateral ones. No statistically significant difference in CDVA between Groups A and B and Groups C and D has been recorded. Final mean spherical equivalent was -3.88±4.73D; in Group A it was -2.74±4.22D, in Group C was -1.08±1.45D, in Group B was -4.82±4.64D and in Group D was -6.81 ± 4.61D.The difference was statistically significant between Group B and D (p=0.01), but not between Group A and C (p=0.14).Twenty-six patients (60.4%) showed post-operative strabismus. Its surgical correction occurred more in patients with multifocal IOL implanted (p=0.038).

Our findings suggest that the use of multifocal IOLs did not show significant advantages in visual development in children following congenital cataract extraction under one year of age if compared with monofocal IOLs.

Our findings suggest that the use of multifocal IOLs did not show significant advantages in visual development in children following congenital cataract extraction under one year of age if compared with monofocal IOLs.

The current review highlights advances in the use of direct-acting antiviral (DAA) agents in the treatment of hepatitis C virus (HCV) in chronic kidney disease (CKD) stages G4-5, end-stage renal disease, and kidney transplantation. The use of DAA to facilitate kidney transplantation of HCV negative recipients with kidneys from HCV-infected donors and in the management of HCV-related cryoglobulinemia are also reviewed.

DAA treatment results in rates of viral clearance (sustained virological response or SVR) of 90-100% in all studied CKD populations, comparable to SVR rates in the general population. DAA treatment allows safe and effective transplantation of HCV viremic kidneys into uninfected recipients.

The high SVR results achieved with DAA allow successful treatment of previously under-treated CKD populations, and encouraged innovative interventions such as the use of HCV-infected donor kidneys to uninfected kidney transplant recipients.

The high SVR results achieved with DAA allow successful treatment of previously under-treated CKD populations, and encouraged innovative interventions such as the use of HCV-infected donor kidneys to uninfected kidney transplant recipients.

Coping with stress is part of self-managing systemic rheumatic diseases. Our objective was to assess stress and coping during the coronavirus disease 2019 (COVID-19) pandemic.

During the pandemic in New York City, patients taking disease-modifying antirheumatic drugs answered open-ended questions about the pandemic's effects on daily life and their rheumatic condition. Themes of stress and coping were discerned from volunteered responses. Patients also completed the standard Generalized Anxiety Disorder (GAD-7) scale/PROMIS Anxiety surveys. Anxiety scores were independent variables in multivariable analyses with stress and coping themes as combined dependent variables.

Of the 112 patients interviewed (86% women; mean age, 50 years), 72 volunteered COVID-19-related stress on their rheumatic condition, home, work, and finances. Patients volunteering stress were younger, had disease longer, were taking more than 1 medication, had worse GAD-7 scores and a positive anxiety screen, and had worse PROMIS scoreswho volunteered coping mechanisms.

The aims of this study were to assess cardiovascular risk in patients with rheumatoid arthritis (RA) classified as low-risk by the Framingham score, before and after the multiplication by 1.5 recommended by the European League Against Rheumatism (EULAR), and to stratify them using carotid and femoral Doppler ultrasound (DUS) in order to optimize the assessment of the asymptomatic cardiovascular disease incidence.

Thirty-five female patients with RA and 35 healthy women (control group), both with low cardiovascular risk by Framingham score, were enrolled in the study (randomized). All of them underwent carotid and femoral DUS studies.

The mean age at diagnosis was 44.57 years, the mean disease duration was 12.11 years and the mean disease activity score according to the Disease Activity Score 28 was 1.91, whereas according to the Clinical Disease Activity Index, it was 6.176. ZCL278 solubility dmso The sample was homogeneous. Within the RA group, 46% showed changes in the carotid and/or femoral DUS, compared with 14% in the control group (p = 0.004). Of the DUS with abnormalities, in the RA group, 31% of the carotid DUS and 81% of the femoral DUS (p = 0.005) showed intima-media thickness and/or atherosclerotic plaques. After EULAR 1.5 multiplication factor, 66% remained low cardiovascular risk. Of these, 35% of the patients showed changes in the carotid and/or femoral DUS, compared with 14% of the control group (p = 0.07).

The EULAR criteria are effective at identifying patients with high cardiovascular risk. Carotid DUS and, especially, femoral DUS are tools that can be used in clinical practice as ways to detect CVD even in its asymptomatic form.

The EULAR criteria are effective at identifying patients with high cardiovascular risk. Carotid DUS and, especially, femoral DUS are tools that can be used in clinical practice as ways to detect CVD even in its asymptomatic form.